Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Stephen Mayo Sells 858 Shares of Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPTGet Rating) Director Stephen Mayo sold 858 shares of the stock in a transaction on Thursday, November 17th. The shares were sold at an average price of $109.92, for a total transaction of $94,311.36. Following the completion of the sale, the director now directly owns 6,387 shares in the company, valued at approximately $702,059.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Sarepta Therapeutics Stock Down 1.3 %

Shares of SRPT opened at $110.55 on Tuesday. The firm has a market cap of $9.70 billion, a P/E ratio of -13.47 and a beta of 1.09. Sarepta Therapeutics, Inc. has a 12-month low of $61.28 and a 12-month high of $120.23. The company’s 50-day moving average price is $110.34 and its 200 day moving average price is $94.43. The company has a current ratio of 4.36, a quick ratio of 3.99 and a debt-to-equity ratio of 3.58.

Sarepta Therapeutics (NASDAQ:SRPTGet Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($2.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.21) by ($1.73). The company had revenue of $230.30 million during the quarter, compared to analysts’ expectations of $234.55 million. Sarepta Therapeutics had a negative net margin of 81.76% and a negative return on equity of 97.37%. The firm’s quarterly revenue was up 21.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.60) earnings per share. On average, sell-side analysts forecast that Sarepta Therapeutics, Inc. will post -8.17 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on SRPT shares. Royal Bank of Canada dropped their target price on shares of Sarepta Therapeutics from $193.00 to $190.00 and set an “outperform” rating on the stock in a report on Thursday, November 3rd. Guggenheim lifted their target price on shares of Sarepta Therapeutics from $100.00 to $122.00 in a research note on Wednesday, August 3rd. StockNews.com initiated coverage on shares of Sarepta Therapeutics in a research report on Wednesday, October 12th. They set a “hold” rating for the company. Robert W. Baird lifted their target price on shares of Sarepta Therapeutics from $110.00 to $152.00 in a report on Thursday, November 3rd. Finally, Morgan Stanley lifted their target price on shares of Sarepta Therapeutics from $135.00 to $141.00 and gave the company an “equal weight” rating in a report on Thursday, October 13th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $143.91.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SRPT. American Century Companies Inc. purchased a new stake in Sarepta Therapeutics during the first quarter worth about $63,986,000. Two Sigma Investments LP increased its stake in Sarepta Therapeutics by 2,475.1% during the third quarter. Two Sigma Investments LP now owns 789,712 shares of the biotechnology company’s stock worth $87,295,000 after purchasing an additional 759,045 shares during the period. Assenagon Asset Management S.A. increased its stake in Sarepta Therapeutics by 154.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,129,016 shares of the biotechnology company’s stock worth $124,801,000 after purchasing an additional 685,845 shares during the period. Wellington Management Group LLP increased its stake in Sarepta Therapeutics by 33.6% during the first quarter. Wellington Management Group LLP now owns 2,680,478 shares of the biotechnology company’s stock worth $209,399,000 after purchasing an additional 673,725 shares during the period. Finally, Thrivent Financial for Lutherans increased its stake in Sarepta Therapeutics by 509.2% during the third quarter. Thrivent Financial for Lutherans now owns 699,483 shares of the biotechnology company’s stock worth $77,321,000 after purchasing an additional 584,654 shares during the period. 82.18% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

(Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

See Also

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.